SUBSCRIBE
SUBSCRIBE
Kate Goodwin

Kate Goodwin

Contributing Writer | News & Features

Kate Goodwin hails from a background primarily in marketing. A passion for health sciences and writing led her to the biopharma news world, and she’s never looked back. She’s been writing for BioSpace for more than two years with a focus on cutting edge research, Alzheimer’s disease and pediatrics. Her free time is filled by her husband, children, Beagles, books, crochet and creative writing. She can be reached at kate.goodwin@biospace.com.

Policy
New Research Points to Why Omicron is Spreading More Rapidly
As the Omicron variant of the SARS-CoV-2 virus sweeps much of the globe, scientists are digging into why this particular mutation is spreading even more rapidly than its predecessors.
December 16, 2021
 · 
2 min read
 · 
Kate Goodwin
Business
Money on the Move: December 8 – 14
During a season of giving, investors were extra generous to these biotech companies this week.
December 15, 2021
 · 
3 min read
 · 
Kate Goodwin
Salvatore Laporta/KONTROLAB /LightRocket via Getty
Business
Novartis Drops Out of COVID-19 Deal with Mesoblast
Novartis has grown weary of waiting, dropping out of its deal to fund Mesoblast’s floundering COVID-19 treatment.
December 14, 2021
 · 
2 min read
 · 
Kate Goodwin
Pavel Kapysh/Shutterstock
Drug Development
Biomarker Data Spurs Possible Comeback of BrainStorm for Amyotrophic Lateral Sclerosis
BrainStorm Cell Therapeutics is making a strong comeback after the FDA was a little impressed with Phase III results of amyotrophic lateral sclerosis treatment.
December 13, 2021
 · 
4 min read
 · 
Kate Goodwin
Genetown
Yale Team Unlocks Genetic Door to Deadly Brain Aneurysms
A team of Yale researchers has found a key to unlocking the deadly mystery of brain aneurysms in adults.
December 10, 2021
 · 
2 min read
 · 
Kate Goodwin
Drug Development
New Study: Fat Cells Are a Reservoir for COVID-19 Infection
Researchers published a study proving that SARS-CoV-2 infects human adipose or fat tissue to multiply and elicit an inflammatory response corresponding with severe COVID-19.
December 9, 2021
 · 
2 min read
 · 
Kate Goodwin
VCG via Getty Images
Drug Development
Bayer Looks to Prostate Cancer Drug for Next Blockbuster
Bayer has high hopes of driving its prostate cancer drug into blockbuster status, meaning over $1 billion in annual sales. This week’s ARASENS trial results should help pave the road.
December 3, 2021
 · 
2 min read
 · 
Kate Goodwin
Courtesy of Yuriko Nakao/Getty Images
Business
Astellas Hopes to Improve Gene Therapy Safety with $1.6 Billion Dyno Deal
With this new collaboration, Astellas will take advantage of Dynos’ next-gen AAV vectors to deliver its gene therapy.
December 2, 2021
 · 
2 min read
 · 
Kate Goodwin
Business
RayzeBio-Partnered Startup Focused on Bringing Radiopharmaceuticals to China
Ablaze has aligned itself with RayzeBio, giving Ablaze a solid start with an in-licensing agreement to bring Rayze’s products to the greater China market.
November 30, 2021
 · 
2 min read
 · 
Kate Goodwin
Genetown
Boston Neighbors Net $256 Million for Treg and Allosteric Therapies
Quell Therapeutics scooped up $156 million in a Series B round this week. The company utilizes regulatory T cells to treat a variety of autoimmune and inflammatory diseases.
November 29, 2021
 · 
3 min read
 · 
Kate Goodwin
Business
Money on the Move: November 17 – 23
Plenty to be thankful for this week for these biopharma companies, especially with the influx of cash.
November 24, 2021
 · 
3 min read
 · 
Kate Goodwin
Policy
With Life-Saving Meds on the Line, FDA Doubles Down on Inspection Goal
The U.S. FDA is making up for Covid-lost time this year, doubling the goal for FY 2021 domestic surveillance inspections for food and medical manufacturing facilities.
November 23, 2021
 · 
2 min read
 · 
Kate Goodwin
Rafael Henrique/SOPA Images/LightRocket via Getty
FDA
Bluebird Spreads Wings After Company Split; REGENXBIO Gets Orphan Nod
The FDA has granted Cambridge-based bluebird Bio a Priority Review of its Biologics License Application for betibeglogene autotemcel (beti-cel).
November 22, 2021
 · 
2 min read
 · 
Kate Goodwin
stop sign with black board backround
Drug Development
Safety Signals Force Merck and Enanta to Scrap HIV and HBV Programs
If the road to success is paved with failures, then the road to an effective, approved drug is paved with flops. Merck and Enanta are adding some painful pavers to their own roads this week.
November 19, 2021
 · 
3 min read
 · 
Kate Goodwin
lucarista/Shutterstock
Drug Development
Novartis Investors Champing at the Bit for Action After Roche Stock Sale
Two weeks after Novartis announced it would sell its nearly one-third voting stake in next-door neighbor Roche, investors are chomping at the bit to find out how that almost $21 billion will be put to work.
November 18, 2021
 · 
3 min read
 · 
Kate Goodwin
Load More